MXPA01002546A - Promocion o inibhicion de angiogenesis y cardiovascularizacion. - Google Patents

Promocion o inibhicion de angiogenesis y cardiovascularizacion.

Info

Publication number
MXPA01002546A
MXPA01002546A MXPA01002546A MXPA01002546A MXPA01002546A MX PA01002546 A MXPA01002546 A MX PA01002546A MX PA01002546 A MXPA01002546 A MX PA01002546A MX PA01002546 A MXPA01002546 A MX PA01002546A MX PA01002546 A MXPA01002546 A MX PA01002546A
Authority
MX
Mexico
Prior art keywords
cardiovascularization
angiogenesis
promotion
inhibition
compositions
Prior art date
Application number
MXPA01002546A
Other languages
English (en)
Inventor
Austin L Gurney
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/019177 external-priority patent/WO1999014234A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MXPA01002546A publication Critical patent/MXPA01002546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Se describen composiciones y metodos para la estimulacion o inhibicion de la angiogenesis y/o cardiovascularizacion en mamiferos, incluyendo humanos. Las composiciones farmaceuticas estan basadas en polipeptidos o antagonistas de estos, que han sido identificados para uno o mas de estos usos. Los desordenes que pueden ser diagnosticados, prevenidos o tratados por las composiciones en la presente, incluyen traumas como heridas, diversos canceres, y desordenes de los vasos incluyendo arterosclerosis e hipertrofia cardiaca.
MXPA01002546A 1998-09-14 1999-09-13 Promocion o inibhicion de angiogenesis y cardiovascularizacion. MXPA01002546A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10026298P 1998-09-14 1998-09-14
PCT/US1998/019177 WO1999014234A2 (en) 1997-09-17 1998-09-14 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/020944 WO2000015792A2 (en) 1998-09-14 1999-09-13 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
MXPA01002546A true MXPA01002546A (es) 2004-06-11

Family

ID=22278870

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01002546A MXPA01002546A (es) 1998-09-14 1999-09-13 Promocion o inibhicion de angiogenesis y cardiovascularizacion.

Country Status (9)

Country Link
EP (1) EP1112361A2 (es)
JP (1) JP2003524599A (es)
KR (1) KR20010085792A (es)
AU (1) AU5920099A (es)
CA (1) CA2341767A1 (es)
IL (1) IL141537A0 (es)
MX (1) MXPA01002546A (es)
WO (1) WO2000015792A2 (es)
ZA (1) ZA200101453B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271973A1 (en) * 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001275707A1 (en) * 2000-07-26 2002-02-05 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
US20040197784A1 (en) * 2001-02-22 2004-10-07 Miano Joseph Michael Retinoid inducible proteins of vascular smooth muscle cells and uses thereof
AU2002363653A1 (en) * 2001-11-13 2003-05-26 Millennium Pharmaceuticals, Inc. Method of using 18080, a human serine carboxypeptidase family member
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CN1309833C (zh) * 1994-04-26 2007-04-11 儿童医学中心公司 血管生成抑制素及其在制备药物中的用途
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
AU6118498A (en) * 1997-02-28 1998-09-18 Institute Of Cytosignal Research, Inc. Intracellular signal transmission inhibitor
WO1999035158A1 (en) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. 36 human secreted proteins
KR100502596B1 (ko) * 1997-09-17 2005-07-22 제넨테크, 인크. 분비 폴리펩티드와 막횡단 폴리펩티드 및 이들을 코딩하는핵산
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
EP1056871A1 (en) * 1998-02-25 2000-12-06 Smithkline Beecham Plc Cprot03, a human cysteine protease

Also Published As

Publication number Publication date
JP2003524599A (ja) 2003-08-19
KR20010085792A (ko) 2001-09-07
WO2000015792A2 (en) 2000-03-23
AU5920099A (en) 2000-04-03
ZA200101453B (en) 2002-02-21
IL141537A0 (en) 2002-03-10
CA2341767A1 (en) 2000-03-23
WO2000015792A3 (en) 2000-09-21
EP1112361A2 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
IL147442A0 (en) Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
IL202176A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
TJ342B (en) Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
EP1140840A4 (en) DIPHENYLUREA WITH SUBSTITUENTS -G (V) -CARBOXYARYLES, INHIBITORS OF RAF KINASE
BG102998A (en) Spiro-piperidine derivatives and their application as therapeutical forms
AP9901478A0 (en) Compounds for the treatment of ischemia.
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
CY2538B1 (en) Tetrahydropyrido compounds
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
MY105946A (en) Antagonists of gm-csf derived from the carboxyl terminus.
WO1999014234A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
MXPA01002546A (es) Promocion o inibhicion de angiogenesis y cardiovascularizacion.
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
WO2001030330A3 (en) Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
AU5441200A (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1083914A4 (en) TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS
WO2001004090A3 (en) Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
BR0013665A (pt) Uso de uma proteìna histacalina, composição farmacêutica, e, método de tratar ou impedir conjuntivite